We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

15 hedge funds and large institutions have $1.53M invested in Moleculin Biotech in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.42% more ownership

Funds ownership: 0.05% → 0.46% (+0.42%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

25% less funds holding

Funds holding: 20 → 15 (-5)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

66% less capital invested

Capital invested by funds: $4.44M → $1.53M (-$2.92M)

Holders
15
Holders Change
-5
Holders Change %
-25%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
3
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$28.1K
2
NFSG
Newbridge Financial Services Group
Florida
+$5.76K
3
FIM
FWL Investment Management
Texas
+$2.35K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.28K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.28K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$557K
2
Renaissance Technologies
Renaissance Technologies
New York
-$111K
3
State Street
State Street
Massachusetts
-$61.3K
4
Citadel Advisors
Citadel Advisors
Florida
-$55.5K
5
Northern Trust
Northern Trust
Illinois
-$46K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$878K -$557K -2,613 -31%
Vanguard Group
2
Vanguard Group
Pennsylvania
$445K +$28.1K +132 +5%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$98.2K +$1.28K +6 +0.9%
BlackRock
4
BlackRock
New York
$73.7K -$1.07K -5 -1%
AWM
5
Atticus Wealth Management
Florida
$19.7K – – –
NFSG
6
Newbridge Financial Services Group
Florida
$4.05K +$5.76K +27 New
TRCT
7
Tower Research Capital (TRC)
New York
$3.67K +$1.28K +6 +32%
Morgan Stanley
8
Morgan Stanley
New York
$2.5K -$3.62K -17 -50%
FIM
9
FWL Investment Management
Texas
$1.64K +$2.35K +11 New
NS
10
NBC Securities
Alabama
$1K +$213 +1 New
SSB
11
Sandy Spring Bank
Maryland
$526 – – –
Osaic Holdings
12
Osaic Holdings
Arizona
$384 – – –
CFO
13
CVA Family Office
Colorado
$201 – – –
Wells Fargo
14
Wells Fargo
California
$112 – – –
NSIM
15
North Star Investment Management
Illinois
$95 – – –
Bank of America
16
Bank of America
North Carolina
$41 – – –
JP Morgan Chase
17
JP Morgan Chase
New York
$41 – – –
NA
18
NewEdge Advisors
Louisiana
$6 – – –
Renaissance Technologies
19
Renaissance Technologies
New York
– -$111K -346 Closed
State Street
20
State Street
Massachusetts
– -$61.3K -190 Closed
Citadel Advisors
21
Citadel Advisors
Florida
– -$55.5K -172 Closed
Northern Trust
22
Northern Trust
Illinois
– -$46K -143 Closed
PJSIMP
23
P.J. Schmidt Investment Management (PJS)
Wisconsin
– -$14.1K -77 Closed
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
– -$11.5K -54 Closed
JE
25
JMAC Enterprises
Pennsylvania
– -$11.3K -35 Closed
1
2

MBRX Hedge Fund Activity: Q1 2024 in Review

15 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2024, worth a combined $1.53M — down 66% from $4.44M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of MBRX and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $28.1K. The largest seller was Armistice Capital, cutting an estimated $557K.

  • 15 institutional investors held Moleculin Biotech (MBRX) as of Q1 2024, down from 20 in Q4 2023.
  • Funds reported $1.53M of Moleculin Biotech stock for Q1 2024, down 66% quarter-over-quarter.
  • 3 funds opened new Moleculin Biotech positions in Q1 2024 and 8 closed out, a net change of -5 holders.
  • The largest Moleculin Biotech buyer in Q1 2024 was Vanguard Group, an estimated $28.1K added.
  • The largest Moleculin Biotech seller in Q1 2024 was Armistice Capital, an estimated $557K sold.

Based on aggregated 13F filings for Q1 2024.